Back to results
US 11,111,297 B2Granted
Antibodies specific for immunoglobulin-like transcript 3 (ILT3) and uses thereof
AssigneeMerck Sharp & Dohme Corp.
InventorsMichael A. Meehl, Philip E. Brandish, Laurence Fayadat-Dilman, Veronica Juan, Carl Mieczkowski, Latika Singh
Life of this patent
Estimating the term…
Abstract
Humanized, non-promiscuous monoclonal antibodies specific for immunoglobulin-like transcript 3 (ILT3), also known as Leukocyte immunoglobulin-like receptor subfamily B member 4 (LILRB4), are described.
Claims21
An antibody or antigen binding fragment that binds the extracellular domain of human immunoglobulin-like transcript 3 (ILT3) having amino acids 1-238 of SEQ ID NO:
- 1, wherein the antibody or antigen binding fragment comprises
- (a) a heavy chain complementarity determining region 1 (HC-CDR1), wherein the HC-CDR1 has the amino acid sequence set forth in SEQ ID NO:
- 17;
- an HC-CDR2, wherein the HC-CDR2 has the amino acid sequence set forth in SEQ ID NO:
- 19, 20, or 21;
- an HC-CDR3, wherein the HC-CDR3 has the amino acid sequence set forth in SEQ ID NO:
- 23;
- and
- (b) a light chain complementarity determining region 1 (LC-CDR1), wherein the LC-CDR1 has the amino acid sequence set forth in SEQ ID NO:
- 34, 35, 36, 37, 38, 39, 40, 41, or 42;
- an LC-CDR2, wherein the LC-CDR2 has the amino acid sequence set forth in SEQ ID NO:
- 43;
- and an LC-CDR3, wherein the LC-CDR3 has the amino acid sequence set forth in SEQ ID NO:
- 44.
11 more elements
An antibody or antigen binding fragment that binds the extracellular domain of human immunoglobulin-like transcript 3 (ILT3) having amino acids 1-238 of SEQ ID NO:
- 1, wherein the antibody or antigen binding fragment comprises
- (a) a heavy chain complementarity determining region 1 (HC-CDR1), wherein the HC-CDR1 has the amino acid sequence set forth in SEQ ID NO:
- 17;
- an HC-CDR2, wherein the HC-CDR2 has the amino acid sequence set forth in SEQ ID NO:
- 20;
- an HC-CDR3, wherein the HC-CDR3 has the amino acid sequence set forth in SEQ ID NO:
- 23;
- and
- (b) a light chain complementarity determining region 1 (LC-CDR1), wherein the LC-CDR1 has the amino acid sequence set forth in SEQ ID NO:
- 41;
- an LC-CDR2, wherein the LC-CDR2 has the amino acid sequence set forth in SEQ ID NO:
- 43;
- and an LC-CDR3, wherein the LC-CDR3 has the amino acid sequence set forth in SEQ ID NO:
- 44.
11 more elements
Dependencies are inferred from the claim text.